Vaccinex Inc (VCNX)

Überblick Nachrichten Preisverlauf Financials Warum fällt VCNX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Vaccinex Inc Stock (VCNX) Company Profile

Vaccinex Inc

Healthcare (1170)

Biotechnology (657)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VCNX's Discussions on Twitter

Vergleichen Sie VCNX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VCNX Vaccinex Inc	0.88	0	0	-22.01M	-18.31M	-85.40
VRTX Vertex Pharmaceuticals Inc	463.27	123.14B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	550.00	60.43B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	324.69	42.07B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	572.71	34.47B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	290.35	27.42B	3.81B	-644.79M	-669.77M	-6.24

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-09-23	Herabstufung	BTIG Research	Buy → Neutral
2018-09-04	Eingeleitet	Ladenburg Thalmann	Buy

Vaccinex Inc Aktie (VCNX) Neueste Nachrichten

Finanzdaten der Vaccinex Inc-Aktie (VCNX)

Vaccinex Inc (VCNX)

Vaccinex Inc Stock (VCNX) Company Profile

Vergleichen Sie VCNX mit anderen Aktien

Vaccinex Inc Stock (VCNX) Upgrades & Downgrades

Vaccinex Inc Aktie (VCNX) Neueste Nachrichten

Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire

Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World

Vaccinex (NASDAQ:VCNX) Shares Down 2.4% – Time to Sell? - Defense World

Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India

Vaccinex to Report Promising New Clinical Results of Neoadjuvant - GuruFocus

Vaccinex presents promising cancer treatment data at ASCO - Investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq

Vaccinex to Report Promising New Clinical Results of - GlobeNewswire

Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewswire

Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire

Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World

Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa

Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times

Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq

Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire

VACCINEX, INC. SEC 10-K Report - TradingView

Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews

Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail

Vaccinex Delays Yearly Report Filing - TipRanks

Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa

Vaccinex director resigns, no disagreement cited - Investing.com India

Stocks in play: Neo Performance Materials Inc. - The Globe and Mail

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire

Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan

Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World

Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News

RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News

Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next? - Defense World

Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR

Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World

United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India

Vaccinex Announces Receipt of Delisting Notification from Nasdaq - GlobeNewswire

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

SIMM Launches WNY Stock Index - The Bona Venture

Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartz

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire

Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewswire

Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success - StockTitan

Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Australia

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire

Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Stocktwits

Finanzdaten der Vaccinex Inc-Aktie (VCNX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VCNX